Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas
Author(s) -
Philip Wong,
Angela BikYu Hui,
Jie Su,
ShiJun Yue,
Benjamin HaibeKains,
Nalan Gökgöz,
Wei Xu,
Jeff Bruce,
Justin Williams,
Charles Catton,
Jay S. Wunder,
Irene L. Andrulis,
Rebecca Gladdy,
Brendan C. Dickson,
Brian O’Sullivan,
FeiFei Liu
Publication year - 2015
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.3926
Subject(s) - microrna , medicine , metastasis , sarcoma , hazard ratio , oncology , undifferentiated pleomorphic sarcoma , biomarker , phenotype , gene expression profiling , proportional hazards model , radiation therapy , cancer research , pathology , soft tissue sarcoma , bioinformatics , cancer , gene expression , biology , gene , confidence interval , biochemistry
A common and aggressive subtype of soft-tissue sarcoma, undifferentiated pleomorphic sarcoma (UPS) was examined to determine the role of micro-RNAs (miRNAs) in modulating distant metastasis. Following histopathologic review, 110 fresh frozen clinically annotated UPS samples were divided into two independent cohorts for Training (42 patients), and Validation (68 patients) analyses. Global miRNA profiling on the Training Set and functional analysis in vitro suggested that miRNA-138 and its downstream RHO-ROCK cell adhesion pathway was a convergent target of miRNAs associated with the development of metastasis. A six-miRNA signature set prognostic of distant metastasis-free survival (DMFS) was developed from Training Set miRNA expression values. Using the six-miRNA signature, patients were successfully categorized into high- and low-risk groups for DMFS in an independent Validation Set, with a hazard ratio (HR) of 2.25 (p = 0.048). After adjusting for other known prognostic variables such as age, gender, tumor grade, size, depth, and treatment with radiotherapy, the six-miRNA signature retained prognostic value with a HR of 3.46 (p < 0.001). A prognostic miRNA biomarker for clinical validation was thus identified along with a functional pathway that modulates UPS metastatic phenotype.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom